0000874015-18-000006.txt : 20180102 0000874015-18-000006.hdr.sgml : 20180102 20180102204916 ACCESSION NUMBER: 0000874015-18-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180101 FILED AS OF DATE: 20180102 DATE AS OF CHANGE: 20180102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HOUGEN ELIZABETH L CENTRAL INDEX KEY: 0001074773 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 18503172 MAIL ADDRESS: STREET 1: 10070 BARNES CANYON ROAD STREET 2: C/O MOLECULAR BIOSYSTEMS INC CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-01-01 0000874015 IONIS PHARMACEUTICALS INC IONS 0001074773 HOUGEN ELIZABETH L C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 SVP, Finance & CFO Common Stock 2018-01-01 2018-01-01 5 J 0 100 42.755 A 10492 D Employee Stock Option (right to buy) 49.25 2018-01-02 2018-01-02 4 A 0 54619 0 A 2019-01-02 2025-01-01 Common Stock 54619 54619 D Reporting 100 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 100 shares may not be sold until July 2, 2018. Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,655 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018. /s/B. Lynne Parshall, attorney-in-fact 2018-01-02